Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 3/20 | 1.00 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.57 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.57 |
| ▸ | DAO | P14920 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2143573 | 1.00 | AHR (1.00) | AHRALOX5PTGS1PTGS2DAO | |
| SCHEMBL2132702 | 1.00 | AHR (1.00) | AHRALOX5PTGS1PTGS2DAO | |
| SCHEMBL260347 | 0.86 | AHR (0.74) | AHRALOX5PTGS1PTGS2DAO | |
| SCHEMBL1795502 | 0.86 | AHR (0.74) | AHRALOX5PTGS1PTGS2DAO | |
| SCHEMBL9679429 | 0.86 | AHR (0.74) | AHRALOX5PTGS1PTGS2DAO | |
| SCHEMBL699666 | 0.86 | AHR (0.74) | AHRALOX5PTGS1PTGS2DAO | |
| SCHEMBL9679426 | 0.86 | AHR (0.74) | AHRALOX5PTGS1PTGS2DAO | |
| SCHEMBL10458457 | 0.86 | AHR (0.74) | AHRALOX5PTGS1PTGS2DAO | |
| SCHEMBL20582895 | 0.86 | AHR (0.74) | AHRALOX5PTGS1PTGS2DAO | |
| SCHEMBL18002529 | 0.84 | AHR (0.72) | AHRALOX5PTGS1PTGS2DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1585713-A1 | NEW STILBENE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR LIGAND ANTAGONISTS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2005-10-19 | — | — | EP | disclosed |
| US-20040147788-A1 | Stilbene derivatives and their use as aryl hydrocarbon receptor antagonistic ligands | INSTITUTE NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (I.N.S.E.R.M.) (FR) | 2004-07-29 | — | — | US | disclosed |
| WO-2004041758-A1 | NEW STILBENE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR LIGAND ANTAGONISTICS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (I.N.S.E.R.M.) (FR) | 2004-05-21 | — | — | WO | disclosed |
| EP-1418164-A1 | New stilbene derivatives and their use as aryl hydrocarbon receptor ligand antagonists | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2004-05-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147788-A1 | Stilbene derivatives and their use as aryl hydrocarbon receptor antagonistic ligands | AHR, HCAR3, HCAR1 | AHR 1/4885ALOX5 1222/4885PTGS1 2187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.